#ADA2020 REDUCE-IT DIABETES: Icosapent ethyl lowers CV event risk in type 2 diabetes
Icosapent ethyl therapy provides robust cardiovascular benefits in statin-treated adults with type 2 diabetes, with large relative and absolute risk reductions in first and total CV events, study data show.…